The Relationship Between ICS LABA Administration and Blood Eosinophil Levels in COPD Patient at USU General Hospital

Olivia Monica Deneuve; Andika Pradana; Amira P Tarigan

doi:10.47353/jsocmed.v3i12.180

The Relationship Between ICS LABA Administration and Blood Eosinophil Levels in COPD Patient at USU General Hospital

Olivia Monica Deneuve
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Sumatera Utara, Adam Malik General Hospital, Medan Indonesia
Andika Pradana
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Universitas Sumatera Utara General Hospital, Medan, Indonesia.
Amira P Tarigan
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Universitas Sumatera Utara General Hospital, Medan, Indonesia

Abstract

Introduction: Blood eosinophil count may predict treatment response in patients with chronic obstructive pulmonary disease (COPD) during acute exacerbations. However, the ability of blood eosinophil counts in stable status to predict eosinophilic.

Method: This was a cohort retrospective study performed Juni-August 2022 to Juni-August 2023. Subject were COPD patients who were treated at the outpatient using ICS LABA therapy. Blood samples measured blood eosinophil levels first and control.

Results: Based on Wilcoxon test test, there was a significant positive positive correlation of eosinophil counts between ICS LABA Administration and Blood Eosinophil Levels in COPD Patient at USU General Hospital.

Conclusion: We demonstrated association between ICS LABA Administration and Blood Eosinophil Levels in COPD Patient (p value = 0.02).

Similar Articles

<< < 4 5 6 7 8

You may also start an advanced similarity search for this article.

PDF

Published at

31. December 2024
https://doi.org/10.47353/jsocmed.v3i12.180
Issue:

Vol. 3 No. 12 (2024): December
Section:

Articles
Keywords:

Blood, Eosinophilia Exacerbation COPD (Chronic Obstructive Pulmonary Disease) GOLD
References:

Mathers CD, Loncar D. Projections of global mortality and burden of disease. PLoS Med 2006; 11: 4-42.

Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015; 8: 9-631.

Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 6: 42-435.

Bafadhel M, Peterson S, De Blas MA, Singh D, Calverley PMA, Pavord ID, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018; 2: 26-117.

Hartl S, Breyer MK, Burghuber OC, Hacker S, Schrott A, Rudzicki W, et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020; 5: 874-1901.

Kolsum U, Southworth T, Jackson N, Singh D. Blood eosinophil counts in COPD patients compared to controls. Eur Respir J. 2019; 4: 633-1900.

Celli B, Fabbri L, Criner G, Wedzicha JA, Martinez FJ, Agusti A, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022; 205: 1-20.

Agusti A, Melen E, DeMeo DL, Breyer-Kohansal R, Faner R, Wouters EF, et al. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med. 2022; 5: 24-512.

Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med. 2022; 5: 497-511.

Cho MH, Hobbs BD, Silverman EK. Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. Lancet Respir Med. 2022; 5: 96-485.

Bardsen T, Roksund OD, Benestad MR, Clemm HH, Halvorsen T, Røksund AB, Markestad T. Tracking of lung function from 10 to 35 years after being born extremely preterm or with extremely low birth weight. Thorax. 2022; 8: 8-790.

Eisner MD, Anthonisen N, Coultas D, Perez-Padilla R, Buist S, Mannino D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 15: 693-718.

Li J, Sun S, Tang R, Qiu H, Wang W, Yan L, et al. Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016; 11: 91-3079.

Erry P. Korelasi antara eosinofil darah dan sputum pasien penyakit paru obstruksi kronik (PPOK) di Rumah Sakit Rujukan Respirasi Nasional Persahabatan. Jakarta. 2019; 1: 1-50.

Shibata Y. Role of ICS/LABA on COPD treatment. Japan. 2016; 1: 1-30.

Babu KS, Kastelik JA, Morjaria JB. Inhaled corticosteroid in chronic obstructive pulmonary disease. J Chron Obstruct Pulmon Dis. 2014; 4: 137-821.
Share:

Z

Deneuve, O. M., Pradana, A., & Tarigan, A. P. (2024). The Relationship Between ICS LABA Administration and Blood Eosinophil Levels in COPD Patient at USU General Hospital. Journal of Society Medicine, 3(12), 374–378. https://doi.org/10.47353/jsocmed.v3i12.180